AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Russia and Ukraine have completed a major prisoner exchange, marking one of the largest swaps since the start of the war. The deal was based on agreem...
Germany and France are aiming to end a long-standing rift over their joint fighter jet project by August, as Chancellor Friedrich Merz and President E...
Senior diplomats from Iran, Russia and China convened in Tehran to coordinate their positions on Iran’s nuclear programme and Western sanctions ahea...
Australia has made a further payment to the United States under the AUKUS nuclear submarine deal. Prime Minister Anthony Albanese confirmed on Wednesd...
Russia and Ukraine held a brief 40-minute meeting in Istanbul on Wednesday, discussing further prisoner exchanges but failing to make progress on a ce...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
The world’s biggest dance music festival faces an unexpected setback as a fire destroys its main stage, prompting a last-minute response from organisers determined to keep the party alive in Boom, Belgium.
Australian researchers have created a groundbreaking “biological AI” platform that could revolutionise drug discovery by rapidly evolving molecules within mammalian cells.
Australian researchers have pioneered a low-cost and scalable plasma-based method to produce ammonia gas directly from air, offering a green alternative to the traditional fossil fuel-dependent Haber-Bosch process.
A series of earthquakes have struck Guatemala on Tuesday afternoon, leading authorities to advise residents to evacuate from buildings as a precaution against possible aftershocks.
The U.S. economy faces a 40% risk of recession in the second half of 2025, JP Morgan analysts said on Wednesday, citing rising tariffs and stagflation concerns.
The World Health Organization (WHO) warned on Tuesday that the world could be on the brink of another chikungunya epidemic, similar to the 2005 outbreak, unless swift measures are implemented to control its spread.
Every Sunday evening at Chicago’s North Avenue Beach, the sound of collective shouting echoes across Lake Michigan – not from protestors, but from Scream Club Chicago, a group gathering to relieve stress by screaming into the open air.
A major study warns that antibiotic-resistant superbugs could kill millions each year while shrinking the global economy by almost $2 trillion annually by 2050, a crisis driven in part by international aid cuts that undermine resistance efforts.
The United States has rejected a global pandemic treaty adopted by the World Health Organization (WHO), saying it threatens national sovereignty and lacks clear language.
Ukrainian President Volodymyr Zelenskyy announced on Thursday that Deputy Prime Minister Olha Stefanishyna, who currently oversees European and Euro-Atlantic integration, has been appointed as Ukraine’s next ambassador to the United States.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment